The global viral vector gene therapy market is entering a transformative era, witnessing rapid expansion and growing relevance across healthcare sectors. From tackling genetic disorders to enabling cutting-edge personalized medicine, this field is redefining how we treat some of the world’s most challenging diseases.
The market’s momentum stems from a combination of major advancements:
Advancing genetic engineering technologies
Rising demand for targeted, long-lasting treatments
Regulatory support and increased research and development investments
These forces are enabling pharmaceutical companies, CROs, and CDMOs to push forward with promising clinical trials and therapeutic breakthroughs.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5737
North America led the market in 2024, driven by advanced healthcare infrastructure and high research activity
Asia-Pacific is projected to grow at the fastest rate through 2034, due to rising investment and healthcare accessibility
Adeno-associated virus vectors dominated the market due to strong safety and clinical effectiveness
Lentivirus vectors are expected to see the highest growth, offering durable gene expression capabilities
Gene therapy applications held the largest revenue share and will continue leading market expansion
Pharmaceutical and biotechnology firms are the primary users of viral vector gene therapy
CROs and CMOs are rapidly expanding in usage, reflecting increased outsourcing trends
Viral vector gene therapy uses engineered viruses to deliver healthy genes into patient cells. These vectors are designed to correct or replace faulty genes, offering highly targeted and potentially curative treatments for genetic, rare, and chronic diseases.
Advancements in vector design and delivery systems have significantly improved the safety and effectiveness of these therapies.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5737
Artificial Intelligence is transforming gene therapy by
Identifying optimal gene targets and vector designs
Enhancing the efficiency of clinical trial development
Improving manufacturing processes
Reducing overall development costs and time
This integration of AI is expected to drive faster commercialization of gene therapies.
In April 2025, Vertex Pharmaceuticals reported positive Phase 3 results for its CRISPR-Cas9-based therapy for sickle cell disease, significantly reducing vaso-occlusive crises.
In April 2024, Pfizer’s Beqvez received FDA approval for hemophilia B. This AAV-based gene therapy reduces the need for frequent clotting factor infusions, showcasing the power of gene correction strategies.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
As diagnostic tools improve, more patients are being identified with genetic diseases that may be treatable through gene therapy. These therapies offer the potential for long-lasting results by addressing the root cause of disease.
Example – In November 2024, the FDA approved Kebilidi, an AAV-based gene therapy for AADC deficiency. The treatment, delivered directly into the brain, enables dopamine production for patients with this rare condition.
Viral vector manufacturing remains highly complex and expensive. It requires specialized equipment, skilled personnel, and strict regulatory compliance. These challenges make scaling production difficult and keep treatment costs high, limiting access and affordability.
Adeno-Associated Virus AAV vectors lead the market due to their low toxicity and targeted delivery capability
Lentivirus vectors are gaining popularity for their ability to integrate genetic material into dividing and non-dividing cells, ideal for long-term gene expression
In 2024, NewBiologix launched the Xcell Platform, designed to enhance viral vector production efficiency. Built on a proprietary cell line, the system supports the screening of multiple rAAV candidates and streamlines data collection for regulatory compliance.
Gene therapy dominates the application segment, driven by advancements in treating rare and chronic conditions
Pharmaceutical and biotechnology companies remain the primary users of viral vector-based therapies
Contract Research Organizations and Contract Manufacturing Organizations are growing rapidly as outsourcing becomes more prevalent
In February 2025, Novartis partnered with a major manufacturer to scale up AAV production and improve manufacturing reliability
In July 2024, Abeona Therapeutics collaborated with Beacon Therapeutics to develop AAV204-based therapies for eye diseases
In May 2023, Regenxbio presented its findings on AAV vector distribution and targeting efficiency at the ASGCT Annual Meeting
With clinical breakthroughs, AI-driven innovations, and increasing investment, the viral vector gene therapy market is positioned for robust growth between 2025 and 2034. As technological and regulatory barriers are overcome, gene therapies will become more accessible, affordable, and impactful across a broader range of diseases.
Source : https://www.towardshealthcare.com/insights/viral-vector-gene-therapy-market-sizing
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More